PT  - JOURNAL ARTICLE
AU  - Mohammed A. Sarhan
TI  - Tuberculosis vaccine
DP  - 2010 Jan 01
TA  - Saudi Medical Journal
PG  - 9--13
VI  - 31
IP  - 1
4099  - http://smj.org.sa/content/31/1/9.short
4100  - http://smj.org.sa/content/31/1/9.full
SO  - Saudi Med J2010 Jan 01; 31
AB  - Tuberculosis (TB) is still one of the leading causes of death from a single infectious agent, killing 1.6 million people each year, mostly in developing countries. The existing vaccines, Bacille Calmette and Guerin (BCG), are efficient in preventing the most severe disseminated forms of disease in children and newborns, but its efficacy against active TB in adults has been challenged by several clinical studies. It is a common opinion that only the development of a new and more effective vaccine against TB would significantly ease the deadly disease. In recent years, looking for a new vaccine or an improved TB vaccine is urgently needed. Such vaccines include new live and attenuated strains of Mycobacterium tuberculosis, improved recombinant BCG strains, subunit and DNA vaccines.